Laurus Labs Limited

rs,

January 24, 2024 To To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 The Listing Department National Stock Exchange of Indi

₹ 3,601

nvestor Presentation | January 24, 2024 Executive Summary  Sustained 9M performance ex-PO, with ₹ 3,601 Cr Revenues, declined 23%. Excluding PO1, growth was 11%  Strengthened Scientific and Research e

23%

24, 2024 Executive Summary  Sustained 9M performance ex-PO, with ₹ 3,601 Cr Revenues, declined 23%. Excluding PO1, growth was 11%  Strengthened Scientific and Research expertise and working towa

11%

Sustained 9M performance ex-PO, with ₹ 3,601 Cr Revenues, declined 23%. Excluding PO1, growth was 11%  Strengthened Scientific and Research expertise and working towards addressing customer commerc

₹ 539

and working towards addressing customer commercial needs and to accelerate our CDMO potential  ₹ 539 Cr EBITDA resulted in a margin of 15%, negative impact from lower asset utilization/higher upfront

15%

r commercial needs and to accelerate our CDMO potential  ₹ 539 Cr EBITDA resulted in a margin of 15%, negative impact from lower asset utilization/higher upfront cost in growth projects and new initi

50%

cost in growth projects and new initiatives  Resilient Gross margins sustaining at healthy level >50% from several quarters  US$ 100mn+ CDMO capex on track, supported by strong business pipeline  O

52%

mization underway to drive long term growth  Underlying financial health of business resilient 52%+ GPM and Executing on strategic partnership. Slower Q3 to rebound  Growing application of new

₹ 576

io – R2 downstream capacity expanded; Ground broken for R3 phase 1 work  9M Capex reported at ₹ 576 Cr; 16% Expansion of small molecules DP capabilities at U2 – by 4 billion unit annually of Reve

16%

wnstream capacity expanded; Ground broken for R3 phase 1 work  9M Capex reported at ₹ 576 Cr; 16% Expansion of small molecules DP capabilities at U2 – by 4 billion unit annually of Revenues

4 billion

k  9M Capex reported at ₹ 576 Cr; 16% Expansion of small molecules DP capabilities at U2 – by 4 billion unit annually of Revenues New Capacities brought on line in FY23 Expected to come on line in F

₹ 2,500

ex FY22-24 (by phase) Optimisation underway Indicative # Large projects by phase 2 Indicative ~₹ 2,500 Cr 2 1.4x Peak1 (5Y) 1.1x Average (5Y) Now  Over 60% of the Capex into API/FDF yet to meaningf